Selumetinib was the most efficacious drug for treating an NF1-associated tumor with approximately 68%–71% PR for inoperable or progressive PNs in children 2 years of age and older and bevacizumab for an NF2-related tumor with about 36%–41% PR for vestibular schwannomas in patients 12 years of age and older. The gene discussed is NF1; the disease is Vestibular schwannoma.